Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Moderna Inc MRNA

Healthcare Biotechnology
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Opinion & Analysis (NDAQ:MRNA)

    Rich TV Live's Stocks to Watch this week (Aug. 23, 2024)

    Rich TV Live August 23, 2024

    Rich TV Live's Stocks to Watch this week (Aug. 16, 2024)

    Rich TV Live August 16, 2024

    Memphasys, Moderna, Paion - Investments in solutions with potential

    Mario Hose June 2, 2020

    Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

    Streetwise Reports May 19, 2020

    BARDA Award Provides 'Lift-off for Biotech's COVID Vaccine'

    Streetwise Reports April 23, 2020

    U.S.-Based Biotech 'Growing into a Giant with AI'

    Streetwise Reports March 9, 2020

    Moderna Shares Climb on Development of mRNA Vaccine for Phase 1 Coronavirus Study

    Streetwise Reports February 26, 2020

    Moderna Shares Rise on the Release of Positive Results from Two mRNA Phase 1 Programs

    Streetwise Reports September 13, 2019